1. Asthma GIF. GINA-2019-main-report-June-2019-wms. 2019.
2. Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. LANCET. 2018;391(10118):350-400.
3. King-Biggs MB. Asthma. ANN INTERN MED. 2019;171(7):C49-C64.
4. McGregor MC, Krings JG, Nair P, et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019;199(4):433-445.
5. Qi J, Yu J, Tan Y, et al. Mechanisms of Chinese Medicine Xinmailong's protection against heart failure in pressure-overloaded mice and cultured cardiomyocytes. Sci Rep. 2017;7:42843.
6. Hao P, Jiang F, Cheng J, et al. Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms. J AM COLL CARDIOL. 2017;69(24):2952-2966.
7. Xing C, Tian Z, Qingyan M, et al. Research Progress of Xiao Qinglong Decoction in Treatment of Bronchial Asthma. Hubei Univ TCM. 2018;20(04):121-125.
8. Wang L, Zheng X, Hui Y, et al. Adjuvant treatment with Xiaoqinglong formula for bronchial asthma: Protocol of systematic review and meta-analysis. Medicine (Baltimore). 2019;98(35):e17053.
9. Guo W, Huang J, Wang N, et al. Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma. FRONT PHARMACOL. 2019;10:1185.
10. Berger SI, Iyengar R. Network analyses in systems pharmacology. BIOINFORMATICS. 2009;25(19):2466-2472.
11. Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
12. Wu W, Yang S, Liu P, et al. Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Radix Puerariae for Treatment of Hypertension. FRONT PHARMACOL. 2020;11:345.
13. Song W, Ni S, Fu Y, et al. Uncovering the mechanism of Maxing Ganshi Decoction on asthma from a systematic perspective: A network pharmacology study. Sci Rep. 2018;8(1):17362.
14. Lv X, Xu Z, Xu G, et al. Investigation of the active components and mechanisms of Schisandra chinensis in the treatment of asthma based on a network pharmacology approach and experimental validation. FOOD FUNCT. 2020;11(4):3032-3042.
15. Martin A, Ochagavia ME, Rabasa LC, et al. BisoGenet: a new tool for gene network building, visualization and analysis. BMC BIOINFORMATICS. 2010;11:91.
16. Tang Y, Li M, Wang J, et al. CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. BIOSYSTEMS. 2015;127:67-72.
17. Kumar A, Butler BM, Kumar S, et al. Integration of structural dynamics and molecular evolution via protein interaction networks: a new era in genomic medicine. Curr Opin Struct Biol. 2015;35:135-142.
18. Jian GH, Su BZ, Zhou WJ, et al. Application of network pharmacology and molecular docking to elucidate the potential mechanism of Eucommia ulmoides-Radix Achyranthis Bidentatae against osteoarthritis. BIODATA MIN. 2020;13:12.
19. Rahman N, Muhammad I, Khan H, et al. Molecular Docking of Isolated Alkaloids for Possible α-Glucosidase Inhibition. Biomolecules. 2019;9(10).
20. Aggarwal BB, Sethi G, Baladandayuthapani V, et al. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J CELL BIOCHEM. 2007;102(3):580-592.
21. Kumar A, Zhang K. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery. FRONT CHEM. 2018;6:315.
22. Cheng SC, Huang WC, S PJ, et al. Quercetin Inhibits the Production of IL-1β-Induced Inflammatory Cytokines and Chemokines in ARPE-19 Cells via the MAPK and NF-κB Signaling Pathways. INT J MOL SCI. 2019;20(12).
23. Endale M, Park SC, Kim S, et al. Quercetin disrupts tyrosine-phosphorylated phosphatidylinositol 3-kinase and myeloid differentiation factor-88 association, and inhibits MAPK/AP-1 and IKK/NF-κB-induced inflammatory mediators production in RAW 264.7 cells. IMMUNOBIOLOGY. 2013;218(12):1452-1467.
24. Zhu S, Wang H, Zhang J, et al. Antiasthmatic activity of quercetin glycosides in neonatal asthmatic rats. 3 BIOTECH. 2019;9(5):189.
25. Antwi AO, Obiri DD, Osafo N. Stigmasterol Modulates Allergic Airway Inflammation in Guinea Pig Model of Ovalbumin-Induced Asthma. Mediators Inflamm. 2017;2017:2953930.
26. Huang X, Pan Q, Mao Z, et al. Kaempferol inhibits interleukin‑1β stimulated matrix metalloproteinases by suppressing the MAPK‑associated ERK and P38 signaling pathways. MOL MED REP. 2018;18(3):2697-2704.
27. Mahajan SG, Mehta AA. Suppression of ovalbumin-induced Th2-driven airway inflammation by β-sitosterol in a guinea pig model of asthma. EUR J PHARMACOL. 2011;650(1):458-464.
28. Liang KL, Yu SJ, Huang WC, et al. Luteolin Attenuates Allergic Nasal Inflammation via Inhibition of Interleukin-4 in an Allergic Rhinitis Mouse Model and Peripheral Blood From Human Subjects With Allergic Rhinitis. FRONT PHARMACOL. 2020;11:291.
29. Bagli E, Stefaniotou M, Morbidelli L, et al. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. CANCER RES. 2004;64(21):7936-7946.
30. Peters MC, McGrath KW, Hawkins GA, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4(7):574-584.
31. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. NAT MED. 2004;10(10):1095-1103.
32. Huang W, Glass CK. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol. 2010;30(8):1542-1549.
33. Oh SH, Park SM, Lee YH, et al. Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma. Respir Med. 2009;103(7):1020-1024.
34. Ali S, Hirschfeld AF, Mayer ML, et al. Functional genetic variation in NFKBIA and susceptibility to childhood asthma, bronchiolitis, and bronchopulmonary dysplasia. J IMMUNOL. 2013;190(8):3949-3958.
35. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-141.
36. Schoettler N, Rodríguez E, Weidinger S, et al. Advances in asthma and allergic disease genetics: Is bigger always better? J Allergy Clin Immunol. 2019;144(6):1495-1506.
37. Ren Y, Su X, Kong L, et al. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. INFLAMM RES. 2016;65(12):995-1008.
38. Yang IV, Lozupone CA, Schwartz DA. The environment, epigenome, and asthma. J Allergy Clin Immunol. 2017;140(1):14-23.
39. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. EUR RESPIR J. 2005;25(3):552-563.
40. Zhang HP, Fu JJ, Fan T, et al. Histone deacetylation of memory T lymphocytes by You-Gui-Wan alleviates allergen-induced eosinophilic airway inflammation in asthma. Chin Med. 2015;10:9.
41. Kim SR, Park HJ, Lee KB, et al. Epithelial PI3K-δ Promotes House Dust Mite-Induced Allergic Asthma in NLRP3 Inflammasome-Dependent and -Independent Manners. Allergy Asthma Immunol Res. 2020;12(2):338-358.
42. Kim JS, Jeong JS, Kwon SH, et al. Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis. Sci Rep. 2020;10(1):7608.
43. Wan Y, Xu L, Liu Z, et al. Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms. BMC Complement Altern Med. 2019;19(1):158.
44. Lee KS, Kim SR, Park SJ, et al. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol. 2006;118(1):120-127.
45. Li X, Shan C, Wu Z, et al. Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway. INFLAMM RES. 2020;69(4):365-373.
46. Meyer N, Akdis CA. Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways. Curr Allergy Asthma Rep. 2013;13(1):1-9.
47. Kim SR, Lee KS, Park HS, et al. HIF-1α inhibition ameliorates an allergic airway disease via VEGF suppression in bronchial epithelium. EUR J IMMUNOL. 2010;40(10):2858-2869.
48. Si LB, Zhang MZ, Han Q, et al. Sensitization of keloid fibroblasts by quercetin through the PI3K/Akt pathway is dependent on regulation of HIF-1α. AM J TRANSL RES. 2018;10(12):4223-4234.
49. Noval RM, Chatila TA. Regulatory T cells in allergic diseases. J Allergy Clin Immunol. 2016;138(3):639-652.
50. Josefowicz SZ, Niec RE, Kim HY, et al. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. NATURE. 2012;482(7385):395-399.
51. Hedrick SM, Hess MR, Doedens AL, et al. FOXO transcription factors throughout T cell biology. NAT REV IMMUNOL. 2012;12(9):649-661.
52. Kerdiles YM, Stone EL, Beisner DR, et al. Foxo transcription factors control regulatory T cell development and function. IMMUNITY. 2010;33(6):890-904.
53. Alam R, Gorska MM. Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma. CLIN EXP ALLERGY. 2011;41(2):149-159.
54. Cheng SC, Huang WC, S PJ, et al. Quercetin Inhibits the Production of IL-1β-Induced Inflammatory Cytokines and Chemokines in ARPE-19 Cells via the MAPK and NF-κB Signaling Pathways. INT J MOL SCI. 2019;20(12).
55. Yung JA, Fuseini H, Newcomb DC. Hormones, sex, and asthma. Ann Allergy Asthma Immunol. 2018;120(5):488-494.